



Review of the Effect of Internet Therapeutic Intervention in Patients With Type 1 and Type 2 Diabetes

Diabetes Care 2014;37:e31–e32 | DOI: 10.2337/dc13-1940

Hugh D. Tildesley,^{1,2} Mary Ellen Conway,³ Stuart A. Ross,⁴ Augustine M. Lee,² Jeremy H.M. Chan,⁵ Adel B. Mazanderani,⁶ Hamish G. Tildesley,⁷ and Adam S. White^{1,2}

The use of the Internet has changed the way health care professionals manage diabetes, with platforms now available allowing patients to upload self-monitoring of blood glucose data and share with their health care provider (1). Previous studies have established the efficacy of Internet blood glucose monitoring systems (1–3).

It is now our standard of care to offer an Internet blood glucose monitoring system to patients. We currently have 1,100 patients enrolled and have outcome data on the first 409 patients. Of the 409 patients, 388 had HbA_{1c} at baseline and at least one subsequent HbA_{1c} determination within 9 months. HbA_{1c} values from 3–9 months were averaged to generate follow-up data. The relationship of reporting frequency and HbA_{1c} change was determined by dividing patients into frequent reporters, who reported more than once per month, and infrequent reporters.

Patients were instructed to upload self-monitoring of blood glucose readings every 2 weeks through their choice of platform including CareLink (Medtronic), meters equipped with report-generating software (Contour USB, Bayer; FreeStyle InsuLinx, Abbott;

iBGStar, Sanofi), and a customized spreadsheet (Excel, Microsoft). All platforms generated reports presenting the mean, SD, and range of glucose values according to time of day. The patient's endocrinologist reviewed the readings and sent feedback to the patient via e-mail. Recommendations included changes in therapy, testing frequency, and lifestyle or encouragement to continue with no changes.

Key results are summarized in Table 1. HbA_{1c} in all type 2 diabetic patients declined from $8.36 \pm 1.35\%$ to $7.91 \pm 0.98\%$ ($P < 0.001$). For type 2 diabetic patients treated with insulin, HbA_{1c} declined from $8.53 \pm 0.82\%$ to $8.12 \pm 0.91\%$ ($P < 0.001$). Type 2 diabetic patients exclusively on oral hypoglycemic agents (OHAs) declined from $8.15 \pm 0.98\%$ to $7.67 \pm 1.29\%$ ($P < 0.001$).

At baseline for type 2 diabetic patients, there was no statistically significant difference in HbA_{1c} values for the groups whether they were frequent or infrequent reporters. At follow-up, it was found that HbA_{1c} in frequent reporters were significantly lower than in infrequent reporters, regardless of treatment ($P < 0.05$).

It was found that type 1 diabetic patients who had "ideal" HbA_{1c} showed little decrement in HbA_{1c} values. When excluding patients with HbA_{1c} < 6.9 ($n = 17$), type 1 diabetic patients showed a decline of $8.12 \pm 1.38\%$ to $7.93 \pm 1.17\%$ ($P < 0.01$).

We observed a trend of less frequent reporting among type 1 diabetic patients with lower HbA_{1c} values. When we excluded patients with HbA_{1c} < 7.4 ($n = 26$), we found frequent reporters had lower follow-up HbA_{1c} than infrequent reporters ($P < 0.05$).

Regardless of type of diabetes or treatment, all patients improved significantly. Additionally, when separated into frequent versus infrequent reporters, we found no differences at baseline. At follow-up, frequent reporters had consistently lower HbA_{1c} values.

Previously, there has been a lack of data to fully demonstrate the efficacy of Internet interventions on type 1 diabetic patients, with most available studies conducted on much smaller sample sizes (4,5). We found Internet intervention to be effective across all groups, including type 1 diabetic patients. The lowering of HbA_{1c}

¹Department of Endocrinology and Metabolism, St. Paul's Hospital, Vancouver, British Columbia, Canada

²Department of Endocrinology and Metabolism, University of British Columbia, Vancouver, British Columbia, Canada

³Department of Medicine, McMaster University, Hamilton, Ontario, Canada

⁴Department of Medicine, University of Calgary, Calgary, Alberta, Canada

⁵Department of Medicine, Vanderbilt University, Nashville, TN

⁶Department of Medicine, Saint George's University, Grenada, West Indies

⁷Department of Psychological and Brain Sciences, Dartmouth College, Hanover, NH

Corresponding author: Hugh D. Tildesley, hdtildesley@gmail.com.

© 2014 by the American Diabetes Association. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

Table 1—Baseline and follow-up HbA_{1c} in frequent and infrequent reporting patients

Type of diabetes	n	Baseline HbA _{1c} (SD)*		Follow-up HbA _{1c} (SD)†		P value
		NGSP, %	IFCC, mmol/mol	NGSP, %	IFCC, mmol/mol	
Type 1‡	115	8.12 (1.38)	65 (15.1)	7.93 (1.17)	63 (12.8)	<0.01
Frequent reporters§	44	8.07 (0.84)	65 (9.2)	7.85 (1.02)	62 (11.1)	
Infrequent reporters§	71	8.14 (1.15)	65 (12.6)	7.98 (1.00)	64 (10.9)	
Type 2 OHA	116	8.15 (0.98)	66 (10.7)	7.67 (1.29)	60 (14.1)	<0.001
Frequent reporters	35	8.03 (1.25)	64 (13.7)	7.48 (0.85)	58 (9.3)	
Infrequent reporters	81	8.21 (1.42)	66 (15.5)	7.75 (1.27)	61 (13.9)	
Type 2 insulin +/- OHA	140	8.53 (0.82)	68 (9.0)	8.12 (0.91)	65 (9.9)	<0.001
Frequent reporters	41	8.42 (1.40)	69 (15.3)	7.86 (1.39)	62 (15.2)	
Infrequent reporters	99	8.57 (1.42)	70 (15.5)	8.22 (1.08)	66 (11.8)	
Type 2	256	8.36 (1.35)	68 (14.8)	7.91 (0.98)	63 (10.7)	<0.001

Baseline HbA_{1c} values were compared with follow-up averages using paired samples *t* tests. Frequent and infrequent reporters were compared at baseline across all defined groups using independent *t* tests and again at follow-up. IFCC, International Federation of Clinical Chemistry and Laboratory Medicine. **P* = NS for frequent reporters compared with infrequent reporters for each type of diabetes. †*P* = 0.05 for frequent reporters compared with infrequent reporters for each type of diabetes. ‡Excluding patient HbA_{1c} <6.9 (*n* = 17). §Excluding patient HbA_{1c} <7.4 (*n* = 26).

improves long-term diabetes outcome and lowers costs. The efficacy of this intervention warrants consideration of coverage for this service by insurance plans.

Funding. This work was supported by the Endocrine Research Society, Vancouver, British Columbia, Canada.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. H.D.T. designed the study, developed the protocol, collected and interpreted data, wrote the manuscript, and reviewed and edited the manuscript. M.E.C., J.H.M.C., and A.B.M. collected the data. S.A.R. contributed to study design and protocol development and reviewed and edited the

manuscript. A.M.L. and H.G.T. analyzed data, wrote the manuscript, and reviewed and edited the manuscript. A.S.W. contributed to study design and protocol development, interpreted data, and reviewed and edited the manuscript. All authors read and approved the final manuscript. H.D.T. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Tildesley HD, Mazanderani AB, Ross SA. Effect of Internet therapeutic intervention on A1C levels in patients with type 2 diabetes treated with insulin. *Diabetes Care* 2010;33:1738–1740
2. Tildesley HD, Wright AW, Chan JH, et al. A comparison of Internet monitoring with

continuous glucose monitoring in insulin requiring type 2 DM. Presented at the 73rd Scientific Sessions of the American Diabetes Association, 22 June 2013, Chicago, IL

3. Tildesley HD, Conway ME, Ross SA, et al. Review of the effect of Internet therapeutic intervention in patients with type 1 and type 2 diabetes. Presented at the 73rd Scientific Sessions of the American Diabetes Association, 22 June 2013, Chicago, IL
4. Health Quality Ontario. Home telemonitoring for type 2 diabetes: an evidence-based analysis. *Ont Health Technol Assess Ser* 2009;9:1–38
5. McCarrier KP, Ralston JD, Hirsch IB, et al. Web-based collaborative care for type 1 diabetes: a pilot randomized trial. *Diabetes Technol Ther* 2009;11:211–217